Physician profile
Amit Mittal
NPI 1134324494
$2,042.25
in general payments reported to CMS, 2019-2025
17 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2022: $220 · 2023: $252 · 2024: $415 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $366.96 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $261.09 | 2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $230.00 | 2024-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $220.00 | 2023-2024 | Yupelri, Yupelri |
| Edwards Lifesciences Corporation | $146.66 | 2019 | |
| Amgen INC. | $133.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $122.54 | 2019 | |
| Medtronic, INC. | $110.12 | 2022 | |
| Idorsia Pharmaceuticals US INC | $110.00 | 2022 | |
| Glaxosmithkline, LLC. | $108.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.89 | 2019 | |
| Lilly USA, LLC | $54.88 | 2024 | Mounjaro |
| Pfizer INC. | $28.82 | 2019 | |
| Scpharmaceuticals INC. | $25.30 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.26 | 2025 | Lifevest |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $21.71 | 2019 | |
| Esperion Therapeutics, INC. | $20.81 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.